December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
The effect of antioxidant and zinc supplements on change in drusen size/area in the Age-Related Eye Disease Study (AREDS)
Author Affiliations & Notes
  • EY Chew
    Bldg 31 Rm 6A52 NEI/NIH Bethesda MD
  • MD Davis
    Fundus Photograph Reading Center
    University of Wisconsin Madison WI
  • JM Seddon
    Department of Ophthalmology Massachusetts Eye and Ear Infirmary Boston MA
  • TE Clemons
    EMMES Corporation Rockville MD
  • LD HubbardAge-Related Eye Disease Study Research Group
    Department of Ophthalmology
    University of Wisconsin Madison WI
  • Footnotes
    Commercial Relationships   E.Y. Chew, None; M.D. Davis, None; J.M. Seddon, None; T.E. Clemons, None; L.D. Hubbard, None. Grant Identification: NEI Contract N01-EY-0-2127
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1903. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      EY Chew, MD Davis, JM Seddon, TE Clemons, LD HubbardAge-Related Eye Disease Study Research Group; The effect of antioxidant and zinc supplements on change in drusen size/area in the Age-Related Eye Disease Study (AREDS) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1903.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To evaluate the effect of high-dose antioxidant and/or zinc supplements on the development of drusen in AREDS. Methods:Participants in AREDS were randomly assigned to receive daily tablets containing (1) antioxidants (vitamin C, vitamin E, and beta carotene); (2) zinc as zinc oxide and copper as cupric oxide; (3) antioxidants plus zinc; or (4) placebo. To assess change in drusen size (development of large drusen OU or of advanced AMD in at least one eye), we identified for analysis 1,805 AREDS participants without advanced AMD in either eye or large drusen OU at baseline. To assess change in drusen area (progression of drusen area to at least 1/2 disc area (DA) in at least one eye), we identified 1,790 AREDS participants without advanced AMD and with drusen area less than 1/16 DA at baseline. Drusen progression in size and area was graded from fundus photographs. Cox proportional hazards analysis was used to evaluate the association. Results:The 5-year progression in drusen size, to large drusen OU or advanced AMD in at least one eye, was 18% for placebo, 20% for antioxidants alone, 18% for zinc alone and 21% for antioxidants plus zinc. The AMD category adjusted risk ratios for progression were 1.00 for antioxidants alone, 0.93 for zinc alone, and 1.07 for antioxidants plus zinc. The 5-year progression in drusen area, to increased drusen area in at least one eye, was 5% for placebo, 4% for antioxidants alone, 5% for zinc alone and 5% for antioxidants and zinc. The AMD category adjusted risk ratios were 0.69 for antioxidants alone, 0.93 for zinc alone, and 0.94 for antioxidants and zinc. Analyses adjusted for age, sex, race, and baseline smoking status did not materially alter the size or direction of these risk ratio estimates. None of the risk ratios were statistically significant (P≷.05). Conclusion:Use of high-dose antioxidant and/or zinc supplementation in AREDS did not have an effect on change in drusen size or area.

Keywords: 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 492 nutritional factors • 391 drusen 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×